文献速递慢性肾脏病肾血管病与高血压急性肾损伤

强化降压对肾脏结局的影响:SPRINT试验基于电子健康记录的长期随访

Effect of Intensive Blood Pressure Control on Kidney Outcomes: Long-Term Electronic Health Record-Based Post-Trial Follow-Up of SPRINT.
PubMed 文献 · Clin J Am Soc Nephrol · 2023-10-25

SPRINT试验将数据与49个研究中心的电子健康记录链接,中位随访8.3年,共3041例参与者。强化降压组在干预阶段eGFR下降斜率更陡(-0.96 vs -0.67 ml/min/1.73 m²/年,P<0.001),且干预期间肾脏事件风险更高,但干预后观察阶段两组斜率无显著差异。

要点

  • 强化降压在干预阶段eGFR下降斜率更陡(-0.96 vs -0.67 ml/min/1.73 m²/年,P<0.001)。
  • 基线无CKD者,干预期间强化组eGFR下降≥30%风险更高(HR 3.27,95%CI 2.43-4.40)。
  • 干预后观察阶段两组eGFR下降斜率无显著差异。

核心结论

  • 强化降压与干预阶段eGFR下降总斜率更陡及肾脏事件风险更高相关,但干预后观察阶段无此关联。

研究设计与样本

  • SPRINT试验数据与49个(共102个)研究中心的电子健康记录链接,使用试验和门诊EHR肌酐值。
  • EHR肌酐值中位可及时间为8.3年,共3041例参与者。

主要发现

  • 干预阶段eGFR下降总斜率:标准治疗组-0.67 ml/min/1.73 m²/年(95%CI -0.79至-0.56),强化治疗组-0.96 ml/min/1.73 m²/年(95%CI -1.08至-0.85),P<0.001。
  • 观察阶段eGFR下降斜率:标准组-1.02 ml/min/1.73 m²/年(95%CI -1.24至-0.81),强化组-0.85 ml/min/1.73 m²/年(95%CI -1.07至-0.64),无显著差异。
  • 基线无CKD者,强化治疗与干预期间eGFR下降≥30%风险更高相关(HR 3.27,95%CI 2.43-4.40),干预后观察阶段无此关联。
  • 基线有CKD者,强化治疗仅与干预阶段eGFR下降风险更高相关(HR 1.95,95%CI 1.03-3.70)。

临床怎么用

  • 强化降压在干预期间可能伴随eGFR下降更快及肾脏事件风险增加,但干预后观察阶段未见持续差异。

局限性

  • 原文未述局限性

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Intensive BP lowering in the Systolic Blood Pressure Intervention Trial (SPRINT) produced acute decreases in kidney function and higher risk for AKI. We evaluated the effect of intensive BP lowering on long-term changes in kidney function using trial and outpatient electronic health record (EHR) creatinine values. METHODS: SPRINT data were linked with EHR data from 49 (of 102) study sites. The primary outcome was the total slope of decline in eGFR for the intervention phase and the post-trial slope of decline during the observation phase using trial and outpatient EHR values. Secondary outcomes included a ≥30% decline in eGFR to <60 ml/min per 1.73 m 2 and a ≥50% decline in eGFR or kidney failure among participants with baseline eGFR ≥60 and <60 ml/min per 1.73 m 2 , respectively. RESULTS: EHR creatinine values were available for a median of 8.3 years for 3041 participants. The total slope of decline in eGFR during the intervention phase was -0.67 ml/min per 1.73 m 2 per year (95% confidence interval [CI], -0.79 to -0.56) in the standard treatment group and -0.96 ml/min per 1.73 m 2 per year (95% CI, -1.08 to -0.85) in the intensive treatment group ( P < 0.001). The slopes were not significantly different during the observation phase: -1.02 ml/min per 1.73 m 2 per year (95% CI, -1.24 to -0.81) in the standard group and -0.85 ml/min per 1.73 m 2 per year (95% CI, -1.07 to -0.64) in the intensive group. Among participants without CKD at baseline, intensive treatment was associated with higher risk of a ≥30% decline in eGFR during the intervention (hazard ratio, 3.27; 95% CI, 2.43 to 4.40), but not during the postintervention observation phase. In those with CKD at baseline, intensive treatment was associated with a higher hazard of eGFR decline only during the intervention phase (hazard ratio, 1.95; 95% CI, 1.03 to 3.70). CONCLUSIONS: Intensive BP lowering was associated with a steeper total slope of decline in eGFR and higher risk for kidney events during the intervention phase of the trial, but not during the postintervention observation phase.

来源:Clin J Am Soc Nephrol,查看原文。版权归原作者所有。

引用

  1. Drawz PE, Lenoir KM, Rai NK, et al. Effect of Intensive Blood Pressure Control on Kidney Outcomes: Long-Term Electronic Health Record-Based Post-Trial Follow-Up of SPRINT. Clin J Am Soc Nephrol. 2023. PMID: 37883184. doi:10.2215/CJN.0000000000000335

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。